Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing.

Published byΣπύρος Ταρσούλη Modified over 5 years ago

Similar presentations

Presentation on theme: "Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing."— Presentation transcript:

1 Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis  Yosuke Togashi, MD, Katsuhiro Masago, MD, PhD, Masahide Fukudo, PhD, Tomohiro Terada, PhD, Yasuaki Ikemi, BPharm, Young Hak Kim, MD, Shiro Fujita, MD, PhD, Kaoru Irisa, MD, Yuichi Sakamori, MD, Tadashi Mio, MD, PhD, Ken-ichi Inui, PhD, Michiaki Mishima, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 5, Pages (May 2010) DOI: /JTO.0b013e3181d32287 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Plasma concentration-time plots of erlotinib and OSI-420 in HD 1 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Plasma concentration-time plots of erlotinib and OSI-420 in HD 2 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Plasma concentration-time plots of erlotinib and OSI-420 in HD 3 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Mean plasma concentration-time plots (± standard deviation) of erlotinib and OSI-420 in the control group on day 1 and day 8 and those in the HD group on day 1, day 8, and day 9. HD shows hemodialysis. The patterns in the HD group were similar to those in the control group. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient 

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient 
Treatment of Pulmonary Epithelioid Hemangioendothelioma with Bevacizumab  Young Hak Kim, MD, Michiaki Mishima, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD 

Treatment of Pulmonary Epithelioid Hemangioendothelioma with Bevacizumab  Young Hak Kim, MD, Michiaki Mishima, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Similar presentations

Ads by Google